Paper36747017
Immune checkpoint inhibitor combinations-current and emerging strategies.
Walsh RJ and 2 others. Br J Cancer, 2023. Cited by 80 papers, by iCite.
Cite this record
ConductScience Library. Immune checkpoint inhibitor combinations-current and emerging strategies. Papers, record 36747017. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36747017
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics3
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immune Checkpoint Inhibitors | Major topic |
| Immunotherapy | Major topic |
| Humans |
Source PubMed
References8
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33811048 | Development of Immunotherapy Combination Strategies in Cancer. | Cancer Discov | 2021 | https://conductscience.org/library/papers/33811048 | PubMed |
| 2 | 35978433 | Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. | J Hematol Oncol | 2022 | https://conductscience.org/library/papers/35978433 | PubMed |
| 3 | 31050707 | Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. | Ann Oncol | 2019 | https://conductscience.org/library/papers/31050707 | PubMed |
| 4 | 35507017 | A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35507017 | PubMed |
| 5 | 32948597 | Revisiting the PD-1 pathway. | Sci Adv | 2020 | https://conductscience.org/library/papers/32948597 | PubMed |
| 6 | 34980128 | Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. | Cancer Cell Int | 2022 | https://conductscience.org/library/papers/34980128 | PubMed |
| 7 | 35228755 | Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. | Nat Med | 2022 | https://conductscience.org/library/papers/35228755 | PubMed |
| 8 | 33580222 | PD-L1 as a biomarker of response to immune-checkpoint inhibitors. | Nat Rev Clin Oncol | 2021 | https://conductscience.org/library/papers/33580222 | PubMed |
Cited by57
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 80 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42958364 | Immune checkpoints: cross-disease insights and clinical dilemmas. | Biomark Res | 2026 | https://conductscience.org/library/papers/42958364 | PubMed |
| 42909707 | Patients' lived experiences of fractures during immune checkpoint inhibitor therapy: a qualitative study. | Arch Osteoporos | 2026 | https://conductscience.org/library/papers/42909707 | PubMed |
| 42823086 | Hormone therapy potentiates chemoimmunotherapy by inducing SUMOylation-mediated immunogenic cell death. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42823086 | PubMed |
| 42716675 | Advancements in Immunotherapy for Lung Cancer: A Meta-Analysis of Clinical Trial Outcomes. | Clin Respir J | 2026 | https://conductscience.org/library/papers/42716675 | PubMed |
| 42699051 | NF-κB-driven immune checkpoint knockdown and cytokine expression in cancer cells for tumor immunotherapy. | iScience | 2026 | https://conductscience.org/library/papers/42699051 | PubMed |
| 42621362 | Biohybrid Salmonella typhimurium for synergistic chemoimmunotherapy via localized chemotherapy and in situ PD-L1 blockade. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42621362 | PubMed |
| 42237783 | Immune checkpoint therapy in pediatric and adolescent lymphomas. | Haematologica | 2026 | https://conductscience.org/library/papers/42237783 | PubMed |
| 42006716 | Carbohydrate polymer-based biomaterials for light-triggered Photo-Immunotherapy: Design strategies, immune mechanisms, and translational outlook. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42006716 | PubMed |
| 41992056 | Immunotherapy in Thyroid Cancer: Current Strategies and Challenges. | Cancer Med | 2026 | https://conductscience.org/library/papers/41992056 | PubMed |
| 41988088 | Pulmonary toxicity of immune checkpoint inhibitors. | Breathe (Sheff) | 2026 | https://conductscience.org/library/papers/41988088 | PubMed |
| 41963297 | Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/41963297 | PubMed |
| 41479921 | Dual checkpoint blockade of PD-1 and Tim-3 by engineered hybrid nanovesicles for enhanced cancer immunotherapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/41479921 | PubMed |
| 41423270 | TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8+ T-cell subsets in lymph nodes and tumors. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/41423270 | PubMed |
| 41305010 | Harnessing Single-Cell RNA-Seq for Computational Drug Repurposing in Cancer Immunotherapy. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41305010 | PubMed |
| 41301839 | Tumor-Draining Lymph Node-Targeted Electrochemotherapy: A Hypothesis for In Situ Cancer Vaccination. | Biomedicines | 2025 | https://conductscience.org/library/papers/41301839 | PubMed |
| 41249701 | TMB as a predictive biomarker for ICI response in TNBC: current evidence and future directions for augmented anti-tumor responses. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/41249701 | PubMed |
| 40631775 | Moving the needle on immune checkpoint inhibitors with novel targets: are we being TIMid or LAGging behind? | Oncologist | 2025 | https://conductscience.org/library/papers/40631775 | PubMed |
| 40612954 | CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence. | Front Immunol | 2025 | https://conductscience.org/library/papers/40612954 | PubMed |
| 40605058 | Immune checkpoint inhibition perturbs neuro-immune homeostasis and impairs cognitive function. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40605058 | PubMed |
| 40561796 | Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy. | Transl Oncol | 2025 | https://conductscience.org/library/papers/40561796 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36747017
GET https://conductscience.org/api/papers/v1/36747017/cited_by?page=2